Leukemia News

Adolescence can be an awkward, transitional time for many people, but for adolescents and young adults living with cancer, these years may be even more confusing and alienating.

The FDA granted fast track designation to several oncology and hematology therapies.

Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia achieved better outcomes, according to results of a retrospective study.

A new voluntary oncology payment model the Biden administration announced earlier this summer has been met with support, as well as concerns, from several cancer organizations.

The FDA granted priority review to omidubicel, an investigational donor-based stem cell therapy for patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.

Frailty assessments are important predictors of future health outcomes among geriatric patients with hematologic malignancies.

Firefighters and EMS providers with low levels of serum IgE who responded to the attack on the World Trade Center on and after Sept. 11, 2001, had significantly higher odds for developing a hematologic malignancy, a recent study reported.

A 66-year-old man is the oldest person yet to possibly be cured of HIV after undergoing a stem cell transplant, researchers announced Wednesday.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

The FDA granted fast track and rare pediatric disease designations to WU-CART-007 for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to a press release from the agent’s manufacturer.